Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bright Minds Biosciences Inc (DRUG)

Bright Minds Biosciences Inc (DRUG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 728,746
  • Shares Outstanding, K 9,732
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,740 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta -6.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.98
  • Number of Estimates 2
  • High Estimate -0.83
  • Low Estimate -1.12
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -9,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.07 +8.11%
on 02/05/26
92.00 -15.30%
on 01/13/26
-8.83 (-10.18%)
since 01/09/26
3-Month
56.27 +38.48%
on 11/14/25
123.75 -37.03%
on 01/06/26
+18.68 (+31.53%)
since 11/11/25
52-Week
23.17 +236.22%
on 06/27/25
123.75 -37.03%
on 01/06/26
+32.36 (+71.03%)
since 02/11/25

Most Recent Stories

More News
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) today closed its recently announced public offering...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the pricing of its previously announced...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the launch of a public offering of common...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3%...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”),...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company’s PWS program, which...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 77.92 (+4.06%)
DRUG.CN : 105.4600 (+2.09%)
BTIG Remains a Buy on Bright Minds Biosciences (DRUG)

BTIG analyst Thomas Shrader maintained a Buy rating on Bright Minds Biosciences yesterday and set a price target of $72.00. The company’s shares closed yesterday at C$80.95.Elevate Your Investing Strategy:...

DRUG : 77.92 (+4.06%)

Business Summary

Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia.

See More

Key Turning Points

3rd Resistance Point 84.14
2nd Resistance Point 81.22
1st Resistance Point 79.57
Last Price 77.92
1st Support Level 75.00
2nd Support Level 72.08
3rd Support Level 70.43

See More

52-Week High 123.75
Fibonacci 61.8% 85.33
Last Price 77.92
Fibonacci 50% 73.46
Fibonacci 38.2% 61.59
52-Week Low 23.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar